InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,408.42
(
-1.73%
)
US TECH 100
17,947.60
(
0.00%
)
Dow Jones
40,345.41
(
-1.01%
)
Brent Oil
71.96
(
0.59%
)
Bitcoin
54,762.42
(
-0.17%
)
Post# of 253062
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 838
Posts 120392
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 107199

Monday, 10/25/2010 7:12:11 PM

Monday, October 25, 2010 7:12:11 PM

Post# of 253062
This is a low-risk undertaking by VRTX/JNJ. Assuming that patient compliance is strong (as it ought to be in an open-label clinical setting where there are no superfluous placebo pills), the only underlying scientific issue is the PK profile of Telaprevir, which by now is well understood. With a typical non-inferiority margin for this kind of study, the likelihood of a non-inferiority finding is very high, IMO.

Any guesses on the quiz question in #msg-55918145?

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up